Global Brain

Boston Medical Sciences is a healthcare company dedicated to reducing colorectal cancer mortality. It develops a non-invasive detection platform that employs artificial intelligence to facilitate virtual bowel cleansing, enhancing examination accuracy and patient comfort. The platform aims to improve patient outcomes by aiding healthcare providers in early detection and treatment decisions.

bitBiome is a synthetic biology company focused on genome analysis of microorganisms using single-cell sequencing. Founded in November 2018 and based in China, it leverages a large proprietary database of natural microbial sequences sourced from environmental collections and built with its microbial single-cell sequencing platform, bit-MAP. The company provides services across single-cell genomics, database screening and shortlisting, and wet-lab evaluation of target sequences, along with directed evolution campaigns to optimize enzymes. By combining sequence data with advanced engineering approaches, bitBiome supports research, drug discovery, and sustainable innovations without the need for prior isolation or cultivation of organisms.

RABO, Inc. is a Japan-based company specializing in the development of Internet of Things (IoT) collar-type wearable devices aimed at monitoring the behavior and health of cats. Founded in 2018 and headquartered in Shibuya, RABO designs and manufactures products such as the Catlog pendant and belt, which continuously tracks cats' activity data for health management purposes. The company also offers the Catlog home and a mobile application, allowing cat owners to review their pets' activity and health metrics, including weight and urine volume. RABO distributes its products primarily through online retail channels, catering to the growing demand for pet technology solutions that enhance the well-being of cats.

Boston Medical Sciences is a healthcare company dedicated to reducing colorectal cancer mortality. It develops a non-invasive detection platform that employs artificial intelligence to facilitate virtual bowel cleansing, enhancing examination accuracy and patient comfort. The platform aims to improve patient outcomes by aiding healthcare providers in early detection and treatment decisions.

ThinkCyte, Inc. is a biotechnology company that specializes in developing an artificial intelligence-enabled, image-free visual cell sorting system, which sorts cells based on their morphology. Founded in 2016 and headquartered in Tokyo, Japan, with an additional office in San Carlos, California, ThinkCyte utilizes advanced optics and machine learning to create its ghost cytometry technology. This innovative approach allows for ultra-high throughput and content-rich analysis of single cells, facilitating research, diagnostics, and therapeutics across various medical disciplines such as drug discovery and cell therapy. The company's cell sorting technology enables researchers to identify and isolate specific cells, including rare ones, in real-time, advancing the capabilities of single-cell analysis.

Healx is a Cambridge, United Kingdom-based biotechnology company that focuses on treating rare diseases. It leverages artificial intelligence and machine learning to accelerate drug discovery and repurposing, pairing computational insights with pharmacology expertise and patient engagement to match therapies to specific diseases. The company uses generative AI to identify new drug candidates and repurpose existing medications with known safety profiles, aiming to lower development risk and cost while addressing unmet needs of patients with rare diseases.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Cykinso, Inc., founded in 2014 and based in Kawasaki-Shi, Japan, specializes in developing and selling direct-to-consumer microbiome testing kits. The company offers a home-testing solution that assesses the state of an individual's intestinal bacteria. Utilizing advanced sequencing technology, Cykinso's kit rapidly analyzes a vast number of DNA sequences to provide users with insights into their gut health. This information helps individuals understand the relationship between their intestinal flora and various lifestyle-related and digestive diseases, enabling them to make informed health decisions based on their gut microbiome data.

Founded in 2017, Chefaa is a Cairo-based company that develops a smart medicine system application. It connects users with local pharmacies for online medication orders and provides medication reminders.

ChromaCode Inc., established in 2012 and based in Carlsbad, California, specializes in molecular diagnostics. The company develops innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using technology licensed from Caltech. ChromaCode's core products are software, reagents, and assays that enhance the multiplexing capabilities of quantitative PCR (qPCR) instruments by fivefold. Additionally, they offer molecular assays and software for various applications such as personalized medicine and pharmaceutical research. One of their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex PCR test detecting common tick-borne pathogens in a single assay. ChromaCode's technology focuses on improving signal processing from life science instrumentation, enabling cost-effective testing of multiple targets simultaneously while integrating into existing laboratory workflows.

Lumen is a company that has developed a portable device and accompanying app that measures an individual's metabolism through a single breath. This technology provides users with real-time insights into their metabolic health, enabling them to receive personalized nutrition recommendations tailored to their unique metabolic data. By using Lumen, individuals can better understand their dietary needs and manage their weight effectively, whether their goals are weight loss, performance optimization, or overall wellness. The company is comprised of a diverse team of scientists, researchers, engineers, and designers dedicated to transforming how people approach their health through improved metabolic awareness.

BackTech is a digital health company based in Kyoto, Japan, that develops health management solutions for working people. Its Pocket Therapist app measures shoulder stiffness and low back pain to support symptom management and reduce medical costs while improving productivity. The company also provides health management information and collaboration tools that visualize organizational productivity and help teams address health issues. Its platform covers mental and physical health content, enabling organizations to support employee well-being and coordinate health management across the workforce.

FidoCure develops AI-driven precision medicine for canine cancer. It analyzes data from naturally occurring canine tumors using next-generation sequencing and clinical information to build a proprietary learning database for cancer analysis. The company provides genomic sequencing services and targeted therapy recommendations to veterinarians, enabling personalized treatment plans. By linking veterinary and human oncology, FidoCure advances comparative oncology, aims to improve outcomes for dogs and to inform drug development that benefits both pets and people.

LIFESCAPES is a research and manufacturing company specializing in brain-computer interface equipment, particularly for neurorehabilitation. The company's technology focuses on aiding stroke patients by enhancing brain plasticity, which allows individuals to overcome limitations and improve their quality of life. LIFESCAPES' devices are designed to extract and analyze brain-wave data in real-time, monitoring the activity of the functional compensation circuits in stroke patients. This innovative approach enables healthcare professionals to assist patients in regaining movement and addressing movement disorders, ultimately facilitating a more normal and fulfilling life for those affected.

Oobli develops healthy, low-calorie protein sweeteners derived from exotic plants. These rare compounds offer great taste without affecting blood sugar levels or gut microbiome. The company has secured regulatory approvals such as FDA 'no questions' letters and GRAS status for multiple proteins.

Craif develops innovative devices for early cancer detection using urine tests. Founded in 2018, the company aims to improve cancer survival rates by enabling painless, accurate, and regular diagnosis through its MicroRNA technology.

Founded in 2017, Chefaa is a Cairo-based company that develops a smart medicine system application. It connects users with local pharmacies for online medication orders and provides medication reminders.

Fast Doctor operates a digital healthcare platform that provides after-hours emergency and remote medical consultations, including online triage, examinations, prescriptions, and home visits. The service enables patients to access urgent care and routine medical services without visiting a hospital, via a mobile application and a network of partner medical institutions. The company arranges nighttime and holiday doctor visits from partner clinics, addressing common conditions such as vertigo, fever, cough, and injuries, and aims to ease pressure on emergency services while improving accessibility and convenience for patients requiring urgent or routine care. Founded in 2016 and based in Tokyo, Japan.

Aroma Bit, Inc. is a Tokyo-based company specializing in the development, production, and sales of electronic equipment and systems, with a focus on compact odor imaging sensors. The company aims to enhance the understanding and utility of scents by creating innovative products and services that digitize olfactory experiences. Aroma Bit's technology allows for the conversion of various odors into visualized patterns, enabling the collection of digital olfactory data. This capability assists businesses in detecting ingredients in food samples and aids care providers in identifying diseases across diverse applications. Through its pioneering approach, Aroma Bit seeks to elevate the significance of olfactory information in various sectors.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

PREVENT Inc. is a healthcare company based in Nagoya, Japan, founded in 2016. It specializes in the prevention of lifestyle-related diseases through innovative medical data analysis and mobile technology. The company develops Mystar, a mobile application designed to support health promotion for patients with conditions such as diabetes, hypertension, and ischemic heart disease. Mystar enables users to log their health data, engage in communication with healthcare providers, and access educational materials based on research to enhance their lifestyle habits. Additionally, PREVENT offers Myscope, which analyzes health examination data to provide predictive simulations and insights for lifestyle improvements. By leveraging academic medical expertise and advanced technology, PREVENT aims to reduce the risk of severe illnesses and enhance the overall health of its users.

Goryo Chemical, Inc. is a Japanese company specializing in the development of fluorescent probes and functional dyes for applications in chemical biology and diagnostics. Founded in 2010 and headquartered in Sapporo, with an additional office in Tokyo, the company offers a range of products including AcidiFluor, CalFluor, GlycoFluor, and MetalloFluor, among others. These fluorescent probes are designed for cellular analysis, assay, and imaging, enabling selective staining of acidic organelles such as lysosomes and late endosomes. Goryo Chemical also provides bioluminescent probes, labeling services, and custom synthesis, catering to various needs in molecularly-targeted drug and immunoassay applications. The company serves its customers through a network of distributors both domestically and internationally.

Healx is a Cambridge, United Kingdom-based biotechnology company that focuses on treating rare diseases. It leverages artificial intelligence and machine learning to accelerate drug discovery and repurposing, pairing computational insights with pharmacology expertise and patient engagement to match therapies to specific diseases. The company uses generative AI to identify new drug candidates and repurpose existing medications with known safety profiles, aiming to lower development risk and cost while addressing unmet needs of patients with rare diseases.

Genomelink operates a digital genetic analysis platform that lets individuals upload their raw DNA data to generate reports on traits, wellness, ancestry, and nutrition. The service translates genomic information into user-friendly interpretations for personal exploration and genetic self-knowledge. It emphasizes data privacy by upholding user ownership of data, implementing ISO-certified security, and offering options to delete data. The company positions itself as a consumer-focused provider of accessible, detailed genomic insights, supporting informed health and lifestyle decisions while ensuring control and transparency over personal genetic information.

Awair is a technology company that develops indoor air quality monitoring devices and a software platform that provides actionable insights to improve indoor environments. Its sensors measure temperature, humidity, CO2, volatile organic compounds, and particulate matter, delivering real‑time data to homeowners, schools, and workplaces. The platform aggregates the data, offers recommendations, and helps users reduce exposure to pollutants, thereby supporting health and cognitive performance. Awair is headquartered in San Francisco and has an additional office in Seoul.